Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed Refractory Multiple Myeloma - PubMed
a day ago
- #multiple myeloma
- #teclistamab
- #debulking chemotherapy
- Bispecific antibodies have transformed multiple myeloma (MM) treatment, but 30-40% of patients experience primary treatment failure.
- Hi-MM, a composite correlate of non-response, includes extramedullary disease, plasma cell leukemia, bone marrow plasmacytosis ≥50%, or recent transfusion.
- Patients without Hi-MM showed an 84-96% ORR, significantly better survival outcomes compared to those with Hi-MM (20-40% ORR).
- Debulking chemotherapy helped 79% of 19 patients respond to teclistamab, especially those no longer meeting Hi-MM criteria.
- All four patients previously refractory to BCMA bispecifics achieved deep responses post-debulking before teclistamab treatment.
- Clinical parameters can predict teclistamab response, and debulking chemotherapy can bridge resistant patients to effective therapy.